The Purple Sky Store
Women's Columbia Pom-Pom Beanie (Tan Embroidered)
Women's Columbia Pom-Pom Beanie (Tan Embroidered)
Couldn't load pickup availability
Embrace winter with warmth and purpose in the Joyful Warmth Support Beanie by Columbia. Designed with a fluffy synthetic pom on top and lined with ultra-soft microfleece, this cozy beanie is perfect for making chilly days a little brighter. The double-layer knit and cuffed design offer added warmth, while the Columbia patch logo brings a touch of classic style.
More than just a winter essential, this beanie supports an important cause. 40% of all revenue from the Joyful Warmth Support Beanie goes to Sky Foundation, a non-profit that funds pancreatic cancer research, helping you make a difference with every wear.
-60% acrylic, 25% nylon, 12% polyester, 3% elastane for a soft, stretchy fit
- 100% polyester microfleece lining for extra comfort
- Synthetic pom on top for a playful touch
- Double-layer knit and cuffed design for optimal warmth
- One size fits most
Note: Stay warm, stay stylish, and support pancreatic cancer research with this cozy beanie.
Share




















Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...